Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun;9(6):103483.
doi: 10.1016/j.esmoop.2024.103483. Epub 2024 Jun 3.

Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer-single versus double checkpoint inhibition

D Marinelli  1 , A Sabatini  2 , E Bengala  2 , F Ciurluini  2 , V Picone  3 , D Santini  3 , F Pietrantonio  4 , D Rossini  5 , C Cremolini  6
Affiliations
Editorial

Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer-single versus double checkpoint inhibition

D Marinelli et al. ESMO Open. 2024 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure CC reports honoraria from Amgen, Bayer, Merck, Roche, and Servier; carries out consulting or advisory roles for Amgen, Bayer, MSD, and Roche; is on the speakers’ bureau for Servier; reports research funding from Bayer, Merck, and Servier; and reports travel, accommodations, and expenses covered by Roche and Servier. FP reports institutional research grants from BMS, Incyte, Agenus, Amgen, Lilly, and AstraZeneca, and personal fees from BMS, MSD, Amgen, Merck-Serono, Pierre-Fabre, Servier, Bayer, Takeda, Astellas, Johnson & Johnson, Rottapharm, Ipsen, AstraZeneca, GSK, Daiichi-Sankyo, Seagen, and BeiGene. DR has received honoraria from Amgen, MSD, Takeda, and Pierre-Fabre. DS is on the advisory board for Angen, Janssen, Astellas, Bayer, Servier, Novartis, MSD, Merck, Pfizer, and Ipsen. DM, AS, EB, FC, and VP have declared no conflicts of interest.

Figures

Figure 1
Figure 1
Progression-free survival (PFS) in patients with microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with first-line immunotherapy or chemotherapy in the KEYNOTE-177 and CheckMate-8HW clinical trials. Chemo, chemotherapy; CI, confidence interval; CM, CheckMate; HR, hazard ratio; Ipi, ipilimumab; KN-177, KEYNOTE-177; Nivo, nivolumab.
See this image and copyright information in PMC

References

    1. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–257. - PMC - PubMed
    1. Llosa N.J., Cruise M., Tam A., et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. - PMC - PubMed
    1. Diaz L.A., Shiu K.K., Kim T.W., et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):659–670. - PMC - PubMed
    1. Westcott P.M.K., Muyas F., Hauck H., et al. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity. Nat Genet. 2023;55(10):1686–1695. - PMC - PubMed
    1. Lenz H.J., Van Cutsem E., Luisa Limon M., et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2022;40(2):161–170. - PubMed

Publication types

MeSH terms

Substances